TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01352416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
Study: NCT03095638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional dolutegravir 10 mg tablet
Description: Single dose of five 10 mg DTG tablets will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional dolutegravir 10 mg tablet
Description: Single dose of five 10 mg DTG tablets will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional dolutegravir 50 mg tablet
Description: Single dose of one 50 mg tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional dolutegravir 50 mg tablet
Description: Single dose of one 50 mg tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
Study: NCT01674270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study: NCT03095638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dispersible dolutegravir 5 mg tablet
Description: Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
Study: NCT01674270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex
Study: NCT01959607

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS 2.2
Description: Single use of the Tobacco Heating System 2.2 (THS 2.2)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS 2.2
Description: Single use of the Tobacco Heating System 2.2 (THS 2.2)
Study: NCT02545517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabipur
Description: Participants in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabipur
Description: Participants in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples were drawn from all participants at Day 1 and then at subsequent year intervals from extension study Day 1 onwards.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples were drawn from all participants at Day 1 and then at subsequent year intervals from extension study Day 1 onwards.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples were drawn from all participants at Day 1 and then at subsequent year intervals from extension study Day 1 onwards.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Chick-Embryo Cell Rabies Vaccine
Description: 1 booster dose of 1.0 mL of Purified Chick-Embryo Cell Rabies Vaccine intramuscular (IM).
Study: NCT02746601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Assessment, Counselling & Resources
Description: A risk assessment tool is completed on a tablet. The results are scanned into the patient's electronic medical record. A healthcare provider gives behavioural counselling on identified risk factors. The patient is given a customized handout that includes health recommendations and resources based on the participant's identified risk factors.
Study: NCT02388035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotaxime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotaxime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Study: NCT03857360

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pentabiocel
Description: Pentabiocel is the trade name of the product containing the probiotic mixture of: Lactobacillus paracasei LMG P-17504, Lactobacillus plantarum CECT 4528, Bifidobacterium breve Bbr8 LMG P-17501, Bifidobacterium breve BL10 LMG P-17500 and Bifidobacterium animalis subsp lactis Bi1 LMG P -17,502.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is composed of maltodextrin which is easily digestible, being absorbed as rapidly as glucose. Maltodextrin listed by the U.S. Food and Drug Administration (FDA) as a safe food additive.
Study: NCT02309983

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation
Description: Electrical stimulation is a rehabilitative approach that generates muscle activity by alternating leg extension and flexion even in individuals who are unable to stand or step independently. Electrical stimulation will be applied to multiple muscles of the lower limb.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: Electrical stimulation is a rehabilitative approach that generates muscle activity by alternating leg extension and flexion even in individuals who are unable to stand or step independently. Electrical stimulation will be applied to multiple muscles of the lower limb.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stand Retraining with Body Weight Support (BWS)
Description: Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stand Retraining with Body Weight Support (BWS)
Description: Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion.
Study: NCT01674270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Casodex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH Agonist
Study: NCT03028714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-based nutrition education
Description: All participants will undertake anthropometric measurements and assessments of blood pressure and blood glucose. They will be also asked to complete online questionnaires with regards to nutrition and physical activity. Participants in the intervention group will receive additional access to a website, providing information about nutrition topics including alcohol and physical activity. Through the website participants will be asked to play online quiz-games related to the nutrition topics. Each play will include game elements such as time, point collection and graphics. Participants will be asked to play the games as much as they want to improve their scores and to use the website as a reference tool.
Study: NCT00246727

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Selected Vegetable and Herb Mix
Description: The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Selected Vegetable and Herb Mix
Description: The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.
Study: NCT02054221

Intervention type: PROCEDURE
Group type: OTHER
Intervention: myoectomy
Description: The scheme of Extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: myoectomy
Description: The scheme of Extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mitral valve surgery
Description: 41 patients will be performed mitral valve replacement with complete excision of the subvalvular apparatus.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mitral valve surgery
Description: 41 patients will be performed mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.
Study: NCT01177553

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: selective laser photocoagulation of communicating vessels
Description: Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Expected Management
Description: Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
Study: NCT02294838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants will undergo MR imaging of the parotid gland pre and post stimulation. Perfusion images will be acquired using a time-resolved, spoiled GE sequence with 1×1×2 mm spatial resolution, approximately one second 3D temporal resolution, and image technique/contrast parameters TR = 2.8 ms and TE = 0.9 ms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Citric acid
Description: 5 mls of 2% citric Acid will be delivered to the oral cavity via a syringe and Tygon tubing at two separate time intervals in order to stimulate the parotid gland during the MRI scanning process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadovist
Description: Upon commencement of the scan, 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered.
Study: NCT01606683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula with GOS, beta-palmitate, acidified milk
Description: Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard infant formula without functional ingredients
Description: Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Study: NCT02858986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D laparoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4K laparoscopy
Study: NCT02373436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Therapy
Description: They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The training will consist of 30 minutes for the transfer package, interview by items of MAL, and 2 hours and 30 minutes with four tasks of Shaping, and Task Practice.~The Transfer Package consists of a compromise agreement, held at the end of the first day of practice, in which the individual undertakes to complete:~The Shaping is a training method that makes it difficult gradually according to the motor capacity of each individual. It will be taken care of including tasks using all joints (shoulder, elbow, wrist and fingers), giving priority to the individual in need.~The individual will be instructed not to remove the trunk of the chair, and each task is repeated 10 times in no more than 45s.~The Task Practice promotes increased motor function during functional activities. For all individuals will be held the same function: meal.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: This group has no intervention. They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
Study: NCT00090142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Montelukast
Description: Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Montelukast
Description: Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
Study: NCT02555306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.0 mg of DE-122
Description: DE-122 Injectable Solution
Study: NCT00545311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Study: NCT00090142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo tablet administered orally as a single witnessed dose before exercise challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo tablet administered orally as a single witnessed dose before exercise challenge
Study: NCT02816593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrogen peroxide 6%
Description: Office; hydrogen peroxide 6%, 3 sessions of 20 minutes of application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrogen peroxide 15%
Description: Office; hydrogen peroxide 15%, 3 sessions of 20 minutes of application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamide Peroxide 10%
Description: Homemade; Carbamide Peroxide 10%, 2 hours per day for 21 days
Study: NCT00545311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01540591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intralipid
Description: IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline 0.9% IV infusion between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
Study: NCT02298166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy (Mitoxantrone, Cytarabine)
Description: Induction therapy:~* Mitoxantrone 10 mg/m² IV, push (8 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT) d 1-3~* Cytarabine 1000 mg/m² IV (500 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT), over 3 hours, d 1-6~Consolidation therapy:~Younger adult patients (18 to 60 yrs):~Cytarabine 1500 mg/m² by i.v infusion over 3 hours BID on days 1-3 (total dose 9000 mg/m²).~Older patients (\> 60 yrs) and or previous allogeneic HCT:~Cytarabine 1000 mg/m² by i.v. infusion over 3 hours BID on days 1-3 (total dose 6000 mg/m²).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chemotherapy (Mitoxantrone, Cytarabine)
Description: Induction therapy:~* Mitoxantrone 10 mg/m² IV, push (8 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT) d 1-3~* Cytarabine 1000 mg/m² IV (500 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT), over 3 hours, d 1-6~Consolidation therapy:~Younger adult patients (18 to 60 yrs):~Cytarabine 1500 mg/m² by i.v infusion over 3 hours BID on days 1-3 (total dose 9000 mg/m²).~Older patients (\> 60 yrs) and or previous allogeneic HCT:~Cytarabine 1000 mg/m² by i.v. infusion over 3 hours BID on days 1-3 (total dose 6000 mg/m²).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Induction therapy:~Placebo to be given as p.o. TID starting d 7+, given continuously thereafter until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Placebo will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with placebo is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with placebo will be given at the same dose tolerated during induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib
Description: Induction therapy:~Crenolanib to be given as p.o. TID starting d 7+, given continuously until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Crenolanib will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with Crenolanib is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with Crenolanib will be given at the same dose tolerated during induction therapy.
Study: NCT02103725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimecrolimus 10 mg/g cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream